Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 June 2023Website:
http://azitrainc.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:40:15 GMTDividend
Analysts recommendations
Institutional Ownership
AZTR Latest News
BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update.
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing m.
Azitra (NYSEMKT: AZTR ) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents. This covers the company's filaggrin-secreting strain of Staphylococcus epidermidis.
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center. The corporate update will highlight Azitra's updates.
Azitra, Inc. (NYSE American: AZTR), a biopharmaceutical company specializing in precision dermatology treatments, shared preclinical data from its platform and pipeline. The findings will be presented on May 17, 2024, in two oral sessions discussing the use of Staphylococcus epidermidis for treating EGFR inhibitor-induced dermal toxicity and cutaneous delivery.
Azitra (NYSEMKT: AZTR ) stock is falling on Wednesday after the pre-clinical biopharmaceutical company announced details for a public share offering. Azitra is selling 16,667,000 shares of AZTR stock for 30 cents per share.
What type of business is Azitra?
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
What sector is Azitra in?
Azitra is in the Healthcare sector
What industry is Azitra in?
Azitra is in the Biotechnology industry
What country is Azitra from?
Azitra is headquartered in United States
When did Azitra go public?
Azitra initial public offering (IPO) was on 20 June 2023
What is Azitra website?
https://azitrainc.com
Is Azitra in the S&P 500?
No, Azitra is not included in the S&P 500 index
Is Azitra in the NASDAQ 100?
No, Azitra is not included in the NASDAQ 100 index
Is Azitra in the Dow Jones?
No, Azitra is not included in the Dow Jones index
When was Azitra the previous earnings report?
No data
When does Azitra earnings report?
Next earnings report date is not announced yet